Oxford Cannabinoid Technologies Holdings (FRA:0CB) Interest Expense : €0.00 Mil (TTM As of Oct. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oxford Cannabinoid Technologies Holdings's interest expense for the six months ended in Oct. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Oct. 2023 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oxford Cannabinoid Technologies Holdings's Operating Income for the six months ended in Oct. 2023 was € -2.76 Mil. Oxford Cannabinoid Technologies Holdings's Interest Expense for the six months ended in Oct. 2023 was € 0.00 Mil. Oxford Cannabinoid Technologies Holdings has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Oxford Cannabinoid Technologies Holdings Interest Expense Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings Interest Expense Chart

Oxford Cannabinoid Technologies Holdings Annual Data

Trend

May18

May19

May20

May21

Apr23

Interest Expense

-0.02

-0.08

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
	May19	Nov19	May20	Nov20	May21	Nov21	Oct22	Apr23	Oct23
Interest Expense	Get a 7-Day Free Trial				-0.08	-	-	-	-

Oxford Cannabinoid Technologies Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oxford Cannabinoid Technologies Holdings's Interest Expense for the six months ended in Oct. 2023 was €0.00 Mil. Its Operating Income for the six months ended in Oct. 2023 was €-2.76 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Oct. 2023 was €0.00 Mil.

Oxford Cannabinoid Technologies Holdings's Interest Coverage for the quarter that ended in Oct. 2023 is calculated as

Oxford Cannabinoid Technologies Holdings had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Oxford Cannabinoid Technologies Holdings PLC has no debt.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

OCTP:UK

Address

267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT

Website

https://www.oxcantech.com

Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines